Transcatheter aortic valve replacement: A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
Study summary
This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form
* 1\. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by the Heart team and underwent TAVR therapy
* 2\. Patients who understand the purpose of the study, agree to participate in the trial and sign the informed consent form
Exclusion Criteria:
* 1\. Patients who cannot provide informed consent
* 2\. Patients who are participating in other clinical trials
Primary outcome measure(s)
All-casuse mortality — 5 years All-casuse mortality including cardiac death and non-cardiac death
Valve-related long-term clinical efficacy — 5 years * Freedom from bioprosthetic Valve Failure (defined as: Valve- related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 hemodynamic valve deterioration
* Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)
* Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.